
EMBI
Healthcare · Biotechnology · $22.5M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Dec 1, 2021 | Time not confirmed | — | -0.00 | — |
| Sep 1, 2021 | Time not confirmed | — | -0.01 | — |
| Jun 2, 2021 | Time not confirmed | — | -0.01 | — |
| Mar 3, 2021 | Time not confirmed | — | -0.01 | — |
| Dec 2, 2020 | Time not confirmed | — | -0.01 | — |
| Sep 30, 2020 | Time not confirmed | — | -0.01 | — |
| Jun 30, 2020 | Time not confirmed | — | -0.01 | — |
| Mar 31, 2020 | Time not confirmed | — | -0.01 | — |
| Dec 31, 2019 | Time not confirmed | — | -0.02 | — |
| Sep 30, 2019 | Time not confirmed | — | -0.04 | — |
| Jun 30, 2019 | Time not confirmed | — | 0.08 | — |
| Mar 31, 2019 | Time not confirmed | — | -0.11 | — |
| Dec 31, 2018 | Time not confirmed | — | -0.05 | — |
| Sep 30, 2018 |
Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases,…
| Time not confirmed |
| — |
| -0.02 |
| — |
| Jun 30, 2018 | Time not confirmed | — | -0.02 | — |
| Mar 31, 2018 | Time not confirmed | — | -0.09 | — |